Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: EGFR and ROS1: Targeting Resistance

Type: Clinical Science Symposium

Time: Friday May 31, 1:00 PM to 2:30 PM

Location: Hall D1

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
9009

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 9009)

Author(s): Eric B. Haura, Byoung Chul Cho, Jong Seok Lee, Ji-Youn Han, Ki Hyeong Lee, Rachel E. Sanborn, Ramaswamy Govindan, Eun Kyung Cho, Sang-We Kim, Karen L. Reckamp, Joshua K. Sabari, Meena Thayu, Kyounghwa Bae, Roland Elmar Knoblauch, Joshua Curtin, Nahor Haddish-Berhane, Laurie Jill Sherman, Matthew V. Lorenzi, Keunchil Park, Joshua Bauml; Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Seoul National University Bundang Hospital, Seoul, South Korea; National Cancer Center, Gyeonggi-Do, South Korea; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; Washington University School of Medicine, St. Louis, MO; Gachon University Gil Medical Center, Incheon, South Korea; Asan Medical Center, Seoul, South Korea; City of Hope Comprehensive Cancer Center, Duarte, CA; NYU School of Medicine, New York, NY; Janssen Research & Development, LLC, Spring House, PA; Janssen Research and Development, Spring House, PA; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Abstract Disclosures

Abstract:

Background: JNJ-372 binds EGFR and cMet to block ligand binding, promote receptor degradation, and trigger antibody-dependent cellular cytotoxicity in models of EGFR-mutated (EGFRm) NSCLC. Here we describe the ongoing phase 1 safety, pharmacokinetics (PK), and activity of JNJ-372 in patients (pts) with NSCLC, including 3rd generation tyrosine kinase inhibitor (3GTKI)-relapsed EGFRm NSCLC and EGFR Exon20ins disease. Methods: Pts received JNJ-372 (140–1400 mg) IV weekly for the first 28-day cycle and biweekly thereafter. 1050–1400 mg doses are being explored in dose expansion. Blood samples were collected for PK analyses. Efficacy by investigator per RECIST v1.1 in pts with EGFRm NSCLC treated at ≥700 mg is presented. Tumors were characterized by next-generation sequencing of circulating tumor (ct)DNA and/or tumor tissue. Results: As of 17 Jan 2019, 116 enrolled pts with NSCLC were treated. Median age was 63 years, 38% were male, 77% were Asian, and 97% had EGFR mutations. Mean duration of treatment was 3.8 months, longest exposure was 20 cycles. The PK data set included pts from Korea (77%) and the US (23%). At the 1050 mg dose, 72% of pts achieved average concentrations above the EC90 based on preclinical models. Adverse events (AEs; ≥20%) were rash (59%), infusion related reaction (58%), paronychia (28%), and constipation (22%). Additional EGFR/cMet-related AEs include stomatitis (17%), pruritis (15%), peripheral edema (11%), and diarrhea (7%). Grade ≥3 AEs were reported in 34% (8% treatment-related) with dyspnea (6%) and pneumonia (3%) most frequently observed. Among response-evaluable pts, 25/88 (28%) achieved best timepoint response of partial response (PR). 10/47 pts with prior 3GTKI therapy had best timepoint response of PR (6 confirmed), including 4 with C797S, 1 with cMet amplification, and 5 without identifiable EGFR/cMet-dependent resistance. 6/20 pts with Exon20ins had best timepoint response of PR (3 confirmed). Conclusions: JNJ-372 has a manageable safety profile consistent with EGFR and cMet inhibition. Preliminary responses were achieved in 3GTKI-relapsed disease, including C797S and cMet amplification, and Exon20ins disease; enrollment in dose expansion is ongoing. Clinical trial information: NCT02609776

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...